Cambridge Investment Research Advisors’s Hologic HOLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-6,203
Closed -$469K 4099
2026
Q1
$469K Sell
6,203
-1,009
-14% -$75.9K ﹤0.01% 2861
2025
Q4
$537K Sell
7,212
-22,699
-76% -$1.66M ﹤0.01% 2650
2025
Q3
$2.02M Sell
29,911
-1,811
-6% -$120K 0.01% 1502
2025
Q2
$2.07M Sell
31,722
-334
-1% -$20K 0.01% 1414
2025
Q1
$1.98M Buy
32,056
+528
+2% +$35K 0.01% 1356
2024
Q4
$2.27M Buy
31,528
+1,246
+4% +$97.3K 0.01% 1277
2024
Q3
$2.47M Sell
30,282
-118
-0.4% -$9.44K 0.01% 1193
2024
Q2
$2.26M Sell
30,400
-712
-2% -$53.4K 0.01% 1212
2024
Q1
$2.42M Buy
31,112
+192
+0.6% +$14.3K 0.01% 1145
2023
Q4
$2.21M Sell
30,920
-668
-2% -$46.5K 0.01% 1133
2023
Q3
$2.19M Sell
31,588
-2,122
-6% -$160K 0.01% 1074
2023
Q2
$2.73M Buy
33,710
+2,270
+7% +$186K 0.01% 989
2023
Q1
$2.54M Sell
31,440
-1,976
-6% -$159K 0.01% 999
2022
Q4
$2.5M Sell
33,416
-6,845
-17% -$487K 0.01% 961
2022
Q3
$2.6M Sell
40,261
-41,265
-51% -$2.86M 0.01% 905
2022
Q2
$5.65M Buy
81,526
+45,239
+125% +$3.36M 0.03% 539
2022
Q1
$2.79M Buy
36,287
+6,373
+21% +$458K 0.01% 956
2021
Q4
$2.29M Buy
29,914
+2,815
+10% +$207K 0.01% 1062
2021
Q3
$2M Buy
27,099
+17,805
+192% +$1.34M 0.01% 1100
2021
Q2
$620K Sell
9,294
-2,297
-20% -$154K ﹤0.01% 1885
2021
Q1
$862K Buy
11,591
+1,662
+17% +$126K ﹤0.01% 1533
2020
Q4
$723K Buy
9,929
+2,931
+42% +$207K ﹤0.01% 1520
2020
Q3
$465K Buy
6,998
+1,630
+30% +$103K ﹤0.01% 1648
2020
Q2
$306K Sell
5,368
-516
-9% -$25.3K ﹤0.01% 1868
2020
Q1
$207K Buy
5,884
+1,501
+34% +$71.5K ﹤0.01% 1910
2019
Q4
$229K Buy
+4,383
New +$218K ﹤0.01% 2110
2018
Q1
Sell
-5,493
Closed -$235K 2187
2017
Q4
$235K Buy
+5,493
New +$219K ﹤0.01% 1817
2017
Q3
Sell
-4,700
Closed -$213K 2029
2017
Q2
$213K Buy
+4,700
New +$207K ﹤0.01% 1715

Other funds holding HOLX

Cambridge Investment Research Advisors's HOLX Position: Q2 2026 in Review

Cambridge Investment Research Advisors sold out of Hologic (HOLX) in Q2 2026, closing a stake of 6,203 shares — an estimated $469K sold.

Cambridge Investment Research Advisors first reported a position in HOLX in Q2 2017 and held it in 28 quarters. The position peaked at $5.65M in Q2 2022. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

  • Cambridge Investment Research Advisors reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,203 Hologic shares in Q2 2026, an estimated $469K.
  • Cambridge Investment Research Advisors first reported a position in Hologic in Q2 2017 and held it in 28 quarters.
  • Cambridge Investment Research Advisors's Hologic position peaked at $5.65M in Q2 2022.
  • 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.